The invention relates to a new crystalline form II of N-benzoyl-staurosporine； compositions containing the same； processes for the preparation thereof； and the use of crystalline form II of of N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans. The invention relates to the amorphous forms of N-benzoyl-staurosporine； compositions containing the same； processes for the preparation thereof； and the use of amorphous N-benzoyl-staurosporine in diagnostic methods or therapeutic treatment of warm-blooded animals, especially humans.
